>

ALK-B Financials

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>ALK</div>
Understanding current and past ALK Abell Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. We suggest to use ALK Abell B fundamental analysis to find out if markets are today mispricing the company. Put another way you can use it to find out if ALK Abell B is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found thirty-three available fundamental indicators for ALK Abell B AS, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all ALK Abell B financials, including its Price to Earning, Price to Sales and the relationship between Shares Outstanding and Price to Book .
View Fundamentals For
Refresh
With this module, you can determine ALK-B financials for your investing period. You should be able to track the changes in ALK Abell individual fundamental values over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
1%1%

Chance of Financial Distress

ALK Abell B AS has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

ALK Abell Company Summary

ALK Abell competes with Zealand Pharma. ALK-Abell AS, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. ALK-Abell AS was founded in 1923 and is headquartered in Hrsholm, Denmark. ALK Abell operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 2379 people.
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentDenmark Stock View All
ExchangeCopenhagen Stock Exchange
ISINDK0060027142
Business AddressBge All 6-8
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.alk.net
Phone45 45 74 75 76
CurrencyDKK - Danish Krone

ALK Abell Key Financial Ratios

ALK-B Financial Ratios Relationships

ALK Abell B AS is number one stock in net income category among related companies. It is number one stock in earnings per share category among related companies .

ALK Abell Market Fundamentals

Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Check out Trending Equities. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page